Ensysce Biosciences Shares Outstanding History (ENSC)
Ensysce Biosciences reported 4.6M shares outstanding at the end of fiscal 2025.
View full Ensysce Biosciences company overviewEnsysce Biosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 4.6M | 3.2M | +237.44% |
| 2024 | 2024-12-31 | 1.4M | 1.1M | +546.41% |
| 2023 | 2023-12-31 | 209,739 | −324,751 | −60.76% |
| 2022 | 2022-12-31 | 534,490 | −697,670 | −56.62% |
| 2021 | 2021-12-31 | 1.2M | −14.5M | −92.19% |
| 2020 | 2020-12-31 | 15.8M | 8.7M | +123.12% |
| 2019 | 2019-12-31 | 7.1M | 1.0M | +17.03% |
| 2018 | 2018-12-31 | 6.0M | −695,248 | −10.32% |
| 2017 | 2017-12-31 | 6.7M | — | — |
Ensysce Biosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.2M | 13.8M | +578.05% |
| Q1 2026 | 2026-03-31 | 9.3M | 7.6M | +464.09% |
| Q4 2025 | 2025-12-31 | 4.6M | 3.2M | +237.44% |
| Q3 2025 | 2025-09-30 | 3.2M | −10.7M | −77.07% |
| Q2 2025 | 2025-06-30 | 2.4M | −5.8M | −70.64% |
| Q1 2025 | 2025-03-31 | 1.6M | −5.7M | −77.56% |
| Q4 2024 | 2024-12-31 | 1.4M | −1.8M | −56.91% |
| Q3 2024 | 2024-09-30 | 13.9M | 11.0M | +384.30% |
| Q2 2024 | 2024-06-30 | 8.2M | 5.5M | +205.31% |
| Q1 2024 | 2024-03-31 | 7.3M | 6.0M | +470.55% |
| Q4 2023 | 2023-12-31 | 3.1M | 2.6M | +488.61% |
| Q3 2023 | 2023-09-30 | 2.9M | 656,546 | +29.74% |
| Q2 2023 | 2023-06-30 | 2.7M | −32.9M | −92.49% |
| Q1 2023 | 2023-03-31 | 1.3M | −28.7M | −95.71% |
| Q4 2022 | 2022-12-31 | 534,490 | −24.1M | −97.83% |
| Q3 2022 | 2022-09-30 | 2.2M | −22.0M | −90.90% |
| Q2 2022 | 2022-06-30 | 35.5M | 11.3M | +46.48% |
| Q1 2022 | 2022-03-31 | 29.9M | 23.7M | +381.17% |
| Q4 2021 | 2021-12-31 | 24.6M | 18.4M | +295.92% |
| Q3 2021 | 2021-09-30 | 24.3M | 18.0M | +287.65% |
| Q2 2021 | 2021-06-30 | 24.3M | 18.0M | +287.65% |
| Q1 2021 | 2021-03-31 | 6.2M | −380,517 | −5.76% |
| Q4 2020 | 2020-12-31 | 6.2M | −150,910 | −2.37% |
| Q3 2020 | 2020-09-30 | 6.3M | 117,603 | +1.92% |
| Q2 2020 | 2020-06-30 | 6.3M | 156,909 | +2.57% |
| Q1 2020 | 2020-03-31 | 6.6M | 556,921 | +9.21% |
| Q4 2019 | 2019-12-31 | 6.4M | 336,106 | +5.57% |
| Q3 2019 | 2019-09-30 | 6.1M | 113,682 | +1.89% |
| Q2 2019 | 2019-06-30 | 6.1M | 90,069 | +1.50% |
| Q1 2019 | 2019-03-31 | 6.0M | 57,903 | +0.97% |
| Q4 2018 | 2018-12-31 | 6.0M | −695,248 | −10.32% |
| Q3 2018 | 2018-09-30 | 6.0M | −1.2M | −16.16% |
| Q2 2018 | 2018-06-30 | 6.0M | — | — |
| Q1 2018 | 2018-03-31 | 6.0M | — | — |
| Q4 2017 | 2017-12-31 | 6.7M | — | — |
| Q3 2017 | 2017-09-30 | 7.2M | — | — |
Ensysce Biosciences shares outstanding trends
Over the last five reported fiscal years, Ensysce Biosciences's shares outstanding moved from 15.8M to 4.6M, a change of −11.2M. The latest reported quarter, Q2 2026, shows 16.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ensysce Biosciences filings at SEC.gov ↗